Interferon and malignant disease - How does it work and why doesn't it always?

Acta Oncologica

Volumn 37, Issue 4, 1998, Pages 331-338

  Grandér, Dan ^a   Einhorn, Stefan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERFERON;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; GROWTH INHIBITION; HUMAN; IMMUNOMODULATION; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROTEIN FAMILY; REMISSION; REVIEW;

EID: 0031928180     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418698430548     Document Type: Review

References (66)

1. Strander H. Interferon treatment of human neoplasia. Adv Cancer Res 1986; 46: 1-265.
2. Einhorn S, Strander H. Interferon treatment of human malignancies A short review. Med Oncol Tumour Pharmacother 1993; 10: 25-9.
3. Öberg K. Endocrine tumours of the gastrointestinal tract: systemic treatment. Anti-Cancer Drugs 1994; 5: 503-19.
4. Wetzler M, Kantarjian H, Kurzrock R, Talpaz M. Interferon-alpha therapy for chronic myelogenous leukaemia. Am J Med 1995; 99: 402-11.
5. Kirkwood JM, Resnick GD, Cole BF. Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma. Semin Oncol 1997; 24 (Suppl 4): S16-23.
6. Smalley RV, Andersen JW, Hawkins, MJ, et al. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med 1992; 327: 1336-41.
7. Ludwig H, Cohen AM, Polliack A, et al. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Ann Oncol 1995; 6: 467-76.
8. Eisenhauer EA, Lippman SM, Kavanagh JJ, et al. Combination 13-cis-retinoic acid and interferon alpha-2a in the therapy of solid tumours. Leukaemia 1994; 8: 1622-5.
9. Folkman J. Angiogenesis. J Biol Chem 1992; 267: 10931-4.
10. van den Hooff A. Stromal involvement in malignant growth. Adv Cancer Res 1988; 50: 159-96.
11. Gresser I, Maury C, Brouty-Boyé D. Mechanism of the antitumour effect of interferon in mice. Nature 1972; 239: 167-8.
12. Gresser I, Kaido T, Maury C, Woodrow D, Moss J, Belardelli F. Interaction of IFN α/β with host cells essential to the early inhibition of Friend erythroleukaemia visceral metastases in mice. Int J Cancer 1994; 57: 604-11.
13. Yasui H, Proietti E, Vignaux F, Eid P, Gresser I. Inhibition of mouse α/β-interferon of the multiplication of α/β-interferon-resistant Friend erythroleukaemia cells cocultured with mouse hepatocytes. Cancer Res 1990; 50: 3533-9.
14. Kolb H, Mittermuller J, Clemm C. Donor Leukocyte transfusions for treatment of recurrent chronic myelogenous leukaemia in marrow transplant patients. Blood 1990; 76: 2462-5.
15. Einhorn S, Åhre A, Blomgren H, Johansson B, Mellstedt H, Strander H. Interferon and natural killer cell activity in multiple myeloma. Lack of correlation between interferon-induced enhancement of natural killer cell activity and clinical response to human interferon-α. Int J Cancer 1982; 30: 167-72.
16. Lane HC, Feinberg J, Davey V, et al. Anti-retroviral effects of interferon-α in AIDS-associated Kaposi's sarcoma. Lancet 1988; 26: 1218-22.
17. Håkansson A, Gustafsson B, Krysander L, Håkansson L. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br J Cancer 1996; 74: 670-6.
18. Dvorak H, Gresser I. Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumours in mice. J Natl Cancer Inst 1989; 81: 497-502.
19. White C, Sondheimer H, Crouch E, Wilson H, Fan L. Therapy of pulmonary hemangiomatosis with recombinant alfa-2a. N Engl J Med 1989; 320: 1197-200.
20. Einhorn S, Strander H. Interferon therapy for neoplastic diseases in man. In vitro and in vivo studies. In: Stinebring WR, Chapple PJ, eds. Human Interferon. Production and Clinical Use. Plenum Publ Corp, 1978: 159-74.
21. Einhorn S, Vanky F, Grandér D, Willems J. Induction of 2′,5′-oligoadenylate synthetase in malignant cells from freshly explained tumour cells. Variability in the susceptibility to interferon. Eur J Cancer 1987; 23: 1607-13.
22. Rosenblum MG, Maxwell BL, Talpaz M, Kelleher PJ, McCredie KB, Gutterman JU. In vivo sensitivity and resistance of CML cells to α-IFN: correlation with receptor binding and induction of 2′,5′-oligoadenylate synthetase. Cancer Res 1986; 46: 4848-52.
23. Grandér D, Öberg K, Lundqvist M-L, Tiensuu Jansson E, Eriksson B, Einhorn S. Interferon-induced enhancement of 2′,5′-oligoadenylate synthetase in mid-gut carcinoid tumours. Lancet 1990; 336: 337.
24. Talpaz M, Rosenblum M, Kurtzrock R, Reuben J, Kantarjian H, Gutterman. J. Clinical and laboratory changes induced by alpha interferon in chronic lymphocytic leukemia - a pilot study. Am J Hematol 1987; 24: 341-50.
25. Ferbus D, Khosravi S, Dumont J, Billard C. In vivo and in vitro induction of 2′,5′-oligoadenylate synthetase by interferon-alpha in nodular non-Hodgkin's lymphoma and correlations with the clinical response. J Biol Regul Homeostat Agents 1990; 4: 127-34.
26. Brenning G, Åhre A, Nilsson K. Correlation between in vitro and in vivo sensitivity to human leukocyte interferon in patients with multiple myeloma. Scand J Haematol 1985; 35: 543-9.
27. Shuai K. Interferon-activated signal transduction to the nucleus. Current Opinion in Cell Biology 1994; 6: 253-9.
28. Gresser I, Bandu M-T, Brouty-Boyé D. Interferon and cell division. IX. Interferon resistant L1210 cells: Characteristics and origin. J Natl Cancer Inst 1974; 52: 553-9.
29. Daniel SK, Pine R, Pfeffer LM, Levy DE, Darnell JE. Cells resistant to interferon are defective in activation of a promoter-binding factor. EMBO J 1988; 7: 3779-83.
30. Nelson N, Marks MS, Driggers PH, Ozato K. Interferon consensus sequence-binding protein, a member of the interferon regulatory factor family, suppresses interferon-induced gene transcription. Mol Cell Biol 1993; 13: 588-99.
31. Xu B, Grandér D, Sangfelt O, Einhorn S. Primary leukaemia cells resistant to α-interferon in vitro are defective in the induction of the DNA-binding factor ISGF-3. Blood 1994; 84: 1942-9.
32. Kanda K, Decker T, Åman P, Wahlström M, von Gabain A, Kallin B. The EBNA2-related resistance towards alpha interferon (IFN-α) in Burkitt's lymphoma cells effects induction of IFN-induced genes but not the activation of transcription factor ISGF-3. Mol Cell Biol 1992; 12: 4930-36.
33. Matikainen S, Ronni T, Hurme M, Pine R. Retinoic acid activates interferon regulatory factor-1 gene expression in myeloid cells. Blood 1996; 88: 114-23.
34. Wong LH, Krauer K, Hatzinisariou I, Devenish RJ, Ralph SJ. The mechanism of resistance to interferons in melanoma cells: Deficiency in signalling at the level of interferon-activated transcription factors. J Interferon Cytokine Res 1995; 15 (Suppl 1): 172.
35. Foster GR, Ackrill AM, Goldin RD, Kerr IM, Thomas HC, Stark GR. Expression of the terminal protein region of hepatitis B virus inhibits cellular response to interferons α and γ and double stranded RNA. Proc. Natl Acad Sci USA 1991; 88: 2888-92.
36. Reich N, Pine R, Levy D, Darnell JE. Transcription of interferon stimulated genes is induced by adenovirus particles but is supppressed by E1A gene products. J Virol 1988; 62: 114-9.
37. De Mayer E, De Mayer-Guiginard J. Interferons and other regulatory cytokines. New York: John Wiley, 1988.
38. Paucker G, Cantell K, Henle W. Quantitative studies on viral interference in suspended L cells. III. Effect of interfering viruses and interferon on the growth rate of cells. Virology 1962; 17: 324-34.
39. Shearer M, Taylor-Papadimitriou J. Regulation of cell growth by interferon. Cancer Met Rev 1987; 6: 199-221.
40. Grandér D, Xu B, Einhorn S. Cytotoxic effect of interferon in primary malignant tumour cells. Studies in various malignancies. Eur J Cancer 1993; 14: 1940-3.
41. Roos G, Leandersson T, Lundgren E. Interferon-induced cell cycle changes in human hemapoietic cell lines and fresh leukemic cells. Cancer Res 1984; 44: 5358-62.
42. Lundblad D, Lundgren E. Block of a glioma cell line in S by interferon. Int J Cancer 1981; 27: 749-54.
43. Balkwill F, Taylor-Papadimitriou J. Interferons affect both G1 and S + G2 in cells stimulated from quiecence to growth. Nature 1978; 274: 798-800.
44. Graña X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995; 11: 211-9.
45. Kimchi A. Cytokine triggered molecular pathways that control cell cycle arrest. J Cell Biochem 1992; 50: 1-9.
46. Sangfelt O, Erickson S, Einhorn S, Grandér D. Induction of Cip Kip and Ink4 cyclin dependent kinase inhibitors by interferon-α in hematopoietic cell lines. Oncogene 1997; 14: 415-23.
47. Yang E, Korsmeyer SJ. Molecular thanatopsis: A discourse on the BCL2 family and cell death. Blood 1996; 88: 386-401.
48. Sangfelt O, Erickson S, Einhorn S, Castro J, Heiden T, Grandér D. Induction of apoptosis and inhibition of cell growth are independent responses of cells to interferon-α in hematopoietic cell lines. Cell Growth Diff 1997; 8: 343-52.
49. Milner AE, Grand RJ, Gregory CD. Effects of interferon-α on human B cells: repression of apoptosis and prevention of cell growth are independent responses of Burkitt lymphoma lines. Int J Cancer 1995; 61: 348-54.
50. Sangfelt O, Einhorn S, Björklund AC, Wiman KG, Okan I, Grandér D. Wild-type p53-induced apoptosis in a Burkitt lymphoma cell line is inhibited by interferon-γ. Int J Cancer 1996; 67: 106-12.
51. Sangfelt O, Österborg A, Grandér D, et al. Response to interferon therapy in patients with multiple myeloma correlates with expression of the Bcl-2 oncoprotein. Int J Cancer 1995; 63: 190-2.
52. Sachs L. Control of normal cell differentiation and the phenotypic reversion of malignancy in myeloid leukemia. Nature 1978; 274: 535-9.
53. Rossi G. Interferons and cell differentiation. In: Grosser I, ed. Interferon 6, London: Academic Press Inc., 1985; 31-68.
54. Östlund L, Einhorn S, Robèrt K-H, Juliusson G, Biberfeld P. Chronic B-lymphocytic leukemia cells proliferate and differentiate following exposure to interferon in vitro. Blood 1986; 67: 152-9.
55. Lindahl P, Leary P, Gresser I. Enhancement by interferon of the expression of surface antigens on murine leukemia L1210 cells. Proc Natl Acad Sci USA 1973; 70: 2785-8.
56. Heron I, Hokland M, Berg K. Enhanced expression of β2-microglobulin and HLA antigens on human lymphoid cells by interferon. Proc Natl Acad Sci USA 1978; 75: 6215-9.
57. Dustin ML, Rothlein R, Bhan AK, Dinarello CD, Springer TA. Induction by IL 1 and interferon-γ: tissue distribution, biochemistry and function of a natural adherence molecule (ICAM-1). J Immunol 1986; 137: 245-54.
58. Mentzer SJ, Faller DV, Burakoff SJ. Interferon-gamma induction of LFA-1-mediated homotypic adhesion of human monocytes. J Immunol 1986; 137: 108-13.
59. Dron M, Tovey M. Isolation of Daudi cells with reduced sensitivity to interferon. I. Characterization. J Gen Virol 1983; 64: 2641-7.
60. INK4 gene. Response to interferon-α therapy in one of the subclones. Leukemia 1996; 10: 909-24.
61. Ahre A, Björkholm M, Österborg A, et al. High doses of natural alpha-interferon in the treatment of multiple myeloma a pilot study from the myeloma group of central Sweden. Eur J Hematol 1988; 41: 123-30.
62. Kirkwood J, Harris J, Vera R, et al. A randomized study of low and high doses of leukocyte a-interferon in metastatic renal cell carcinoma: The American Cancer Society collaborative trial. Cancer Res 1985; 45: 863-71.
63. van der Molen L, Duffey P, Urba W. Low dose vs high dose recombinant interferon α-2a treatment in favorable histology non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 1989; 8: 255.
64. von Wussow P, Pralle H, Hochkeppel H, et al. Effective natural interferon-α therapy in recombinant interferon-α-resistant patients with hairy cell leukemia. Blood 1991; 78: 38-43.
65. von Wussow P, Jakschies D, Freund M. Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha. Brit J Haematol 1991; 78: 210-6.
66. Finter NB. Why are there so main subtypes of alpha-interferons? J Interferon Res 1991; Special issue, January, 185 94.